| 8.43 0.97 (13%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 47.94 | 1-year : | 73.29 |
| Resists | First : | 41.05 | Second : | 62.75 |
| Pivot price | 38.79 |
|||
| Supports | First : | 5.94 | Second : | 4.95 |
| MAs | MA(5) : | 7.27 |
MA(20) : | 43.05 |
| MA(100) : | 47.74 |
MA(250) : | 46.32 |
|
| MACD | MACD : | -11.6 |
Signal : | -6 |
| %K %D | K(14,3) : | 2.9  |
D(3) : | 2.2 |
| RSI | RSI(14): 21.5 |
|||
| 52-week | High : | 62.75 | Low : | 5.94 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MLTX ] has closed above bottom band by 16.1%. Bollinger Bands are 656.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.51 - 8.55 | 8.55 - 8.58 |
| Low: | 7.42 - 7.46 | 7.46 - 7.49 |
| Close: | 8.37 - 8.43 | 8.43 - 8.49 |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Sun, 05 Oct 2025
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Sat, 04 Oct 2025
MoonLake Immunotherapeutics (MLTX): Assessing Valuation Following Phase 3 Trial Miss and Legal Scrutiny - Yahoo Finance
Fri, 03 Oct 2025
Why MoonLake Immunotherapeutics (MLTX) Is Down 86.8% After Sonelokimab Phase 3 Trial Misses Key Goal - simplywall.st
Fri, 03 Oct 2025
MoonLake Immunotherapeutics down 88% at $7.67 after Phase 3 HS data - MSN
Fri, 03 Oct 2025
MLTX INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Morningstar
Wed, 01 Oct 2025
Major Stakeholder Sells Millions in MoonLake Immunotherapeutics Stock! - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 95 (%) |
| Shares Short | 4,950 (K) |
| Shares Short P.Month | 5,370 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25 % |
| Return on Equity (ttm) | -40.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -166 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -3.03 |
| PEG Ratio | 0 |
| Price to Book value | 1.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|